Neovascularization, increased basal membrane thickness and increased airway smooth muscle (ASM) bulk are hallmarks of airway remodelling in asthma. In this study, we examined connective tissue growth factor (CTGF) dysregulation in human lung tissue and animal models of allergic airway disease. Immunohistochemistry revealed that ASM cells from patients with severe asthma (A) exhibited high expression of CTGF, compared to mild and non-asthmatic (NA) tissues. This finding was replicated in a sheep model of allergic airways disease. In vitro, transforming growth factor (TGF)-b increased CTGF expression both in NA-and A-ASM cells but the expression was higher in A-ASM at both the mRNA and protein level as assessed by PCR and Western blot. Transfection of CTGF promoter-luciferase reporter constructs into NA-and A-ASM cells indicated that no region of the CTGF promoter (À1500 to +200 bp) displayed enhanced activity in the presence of TGF-b.
However, in silico analysis of the CTGF promoter suggested that distant transcription factor binding sites may influence CTGF promoter activation by TGF-b in ASM cells. The discord between promoter activity and mRNA expression was also explained, in part, by differential post-transcriptional regulation in A-ASM cells due to enhanced mRNA stability for CTGF. In patients, higher CTGF gene expression in bronchial biopsies was correlated with increased basement membrane thickness indicating that the enhanced CTGF expression in A-ASM may contribute to airway remodelling in asthma.
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| INTRODUCTION
Asthma is a common, chronic respiratory disease affecting more than 300 million people worldwide. 1 The main characteristics of asthma are airway inflammation, airway hyper-responsiveness and airway remodelling. 2 The structural changes in the airways, termed airway remodelling, include increased airway smooth muscle (ASM) bulk, increased basal membrane thickness and vascular expansion. 3, 4 The extent of airway way remodelling correlates with several clinical features of asthma [5] [6] [7] [8] and agents that normalize the remodelling response potentially improve asthma symptoms. [9] [10] [11] Once considered a manifestation of chronic inflammation, recent studies have identified remodelling is a separate but parallel component of the asthmatic process. 12 In asthma, the observed increase in ASM cell bulk and contractility directly mediates airway narrowing and is central to the process of airway remodelling. Increased ASM number correlates with increased reticular basement membrane (BM) thickness and eosinophilia, but not neutrophilia. 13 Further, the secretory profiles of ASM from asthmatic patients differ significantly from those of nonasthmatic patients suggesting that paracrine signalling from the ASM in may have as much to do with airway remodelling as their contractile state (reviewed in Ref. [14] ). Ultimately, the increased deposition of extracellular matrix (ECM) proteins by ASM cells in asthma is key to the airway narrowing that takes place. 12, [15] [16] [17] [18] Often this is a response to an imbalance in the cytokines/growth factors present in their local milieu. 3 In lung tissue, ASM cells are a potent source of connective tissue growth factor (CTGF), a member of the cysteine-rich 61, CTGF, nephroblastoma (CCN) family of proteins. 19 Our previous studies have shown greater CTGF expression in primary asthmatic (A)-ASM cells than non-asthmatic (NA)-ASM cells after TGF-b treatment. [20] [21] [22] CTGF controls ECM deposition and ultimately airway biomechanics through changes to collagen deposition which increase ECM density and airway stiffness. 23 Indeed, the increased stiffness of the matrix in which asthmatic ASM cells are embedded promotes a more proliferative and pro-inflammatory ASM phenotype. 
| CTGF promoter constructs
A Gluc-on reporter plasmid containing the full-length CTGF promoter (À1500 to +200 bp) driving expression of a secreted Gaussia luciferase was purchased from GeneCopoeia (Cat. HPRM25713-PG04, Rockville, MD, USA). A series of 5 0 deleted constructs were generated by PCR using the primers shown in Cells were stimulated with TGF-b1 (1 ng/mL for ASM and 10 ng/mL for NIH-3T3) 24 hours after transfection, for a further 24 hours. F I G U R E 1 Connective tissue growth factor (CTGF) expression is increased in house dust mite (HDM)-induced allergic airway disease in sheep lungs. CTGF expression in a model of allergic airway disease was assessed by immunohistochemistry in HDM-and saline-exposed (sham control) lung segments from the same sheep 30 (n = 5).
Isotype-matched negative control antibody on serial sections shown for comparison. Representative images shown for each group former asthma patients. All patients originated from cohorts investigated earlier by our research group, and a set of previously acquired clinical data is available 31, 32 . The study protocol was approved by the University Medical Center Groningen medical ethics committee. All patients gave their written informed consent.
For full patient information and details relating to RNA isolation and sequencing, refer to Appendix S1. 
| Statistical analysis
Data were tested for normal distribution and analysed via a 2-way analysis of variance (ANOVA) with Bonferroni post-test. A P-value less than .05 was considered to be statistically significant (P < .05). 
| Tissue specific genetic elements indicate CTGF regulation in lung tissue is unique
To assess whether our promoter construct was indeed inducible by TGF-b and to determine whether CTGF regulation in ASM was analysis, we used human lung fibroblasts as previously no differences in gene expression were detected between lung fibroblasts and ASM cells, indicating highly similar gene expression regulation. 35 There was a strong region of activity immediately upstream of the CTGF transcriptional start site in HUVECs (À1300 to À200 bp), which was less active in human lung fibroblasts ( Figure 4A ). This region spanned the À1500 bp promoter construct we had analysed ( Figure 4B ), and contained several validated SMAD and TGF-b response elements previously reported to drive CTGF expression in other species (Figure 4C , Table 3) . 25, 27, 36 However, an alternate genomic region 5 0 to the (À1300 to À200 bp) site (À4200 to À2400 bp) showed robust H3K27Ac binding in lung cells but relatively low activity in HUVECs 
| CTGF gene expression is unchanged in mild asthmatic patients but relates to BM thickness
Immunohistochemical staining showed CTGF protein expression was concentrated in the ASM area in human lung tissue, with enhanced detection visible in asthmatic tissues, particularly from severe asthma patients ( Figure 6A) . No difference in CTGF mRNA expression (Figure 6B) was detected between bronchial biopsies derived from mild to moderately severe asthma patients (n = 69) and healthy controls (n = 77). In addition, within asthmatic patients, we found a significant relationship between CTGF expression and BM thickness (b AE SE 0.472 AE 0.174, P = .008, Figure 6C ) suggesting ASMderived CTGF expression may influence airway narrowing and remodelling in asthma. In contrast, higher CTGF expression in asthmatic patients was not associated with lower FEV1% predicted (Figure 6D) , more severe bronchial hyper-responsiveness ( Figure 6F ) or higher % eosinophil levels in sputum ( Figure 6E ).
| DISCUSSION
This is the first study that has focused on the molecular regulation We also showed that CTGF mRNA stability was enhanced in A-ASM cells. Chowdhury and colleagues previously showed this to be mediated by p38 in bladder smooth muscle cells. 37 However, our previous data conclusively showed this pathway is not involved with CTGF regulation by TGF-b in A-ASM. 22 The mechanism underlying this enhanced CTGF mRNA stability is currently unknown. [50] [51] [52] The thicker BM of asthmatic airways also has an altered elastic modulus compared to healthy airways. 53 The increased ECM stiffness that accompanies such a change is likely to contribute to the pro-remodelling environment found in asthmatic airways as stiffer matrices promote angiogenesis 54, 55 and ASM cell proliferation. 53 Indeed, stiffer matrices may also enhance CTGF expression through Taz activation, 56,57 completing a positive feedback loop in the asthmatic airway that would co-ordinate all aspects of airway remodelling (ASM bulk, neovascularization and BM thickening).
In conclusion, our data strongly suggest that the unique regula- 
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